Prophylactic antibiotic therapy for chronic obstructive pulmonary disease (COPD)

Cochrane Database of Systematic Reviews

Volumn 2018, Issue 10, 2018, Pages

  Herath, Samantha C ^a   Normansell, Rebecca ^b   Maisey, Samantha ^c   Poole, Phillippa ^d  

^a Department of Respiratory and Sleep Medicine   (Australia)

^b ST GEORGE S HOSPITAL   (United Kingdom)

^c ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^d UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; AZITHROMYCIN; CLARITHROMYCIN; DOXYCYCLINE; ERYTHROMYCIN; MACROLIDE; MOXIFLOXACIN; PLACEBO; ROXITHROMYCIN; AMOXICILLIN; ANTIINFECTIVE AGENT; CLAVULANIC ACID; COTRIMOXAZOLE; HETEROCYCLIC COMPOUND; QUINOLINE DERIVATIVE; QUINOLONE DERIVATIVE;

ALL CAUSE MORTALITY; ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; CARDIOVASCULAR DISEASE; CHLAMYDIAL PNEUMONIA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL PRACTICE; COMBINATION DRUG THERAPY; CONFIDENCE INTERVAL; DATA ANALYSIS; DATA EXTRACTION; DATA SYNTHESIS; DISEASE DURATION; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG HYPERSENSITIVITY; DRUG INDUCED DISEASE; DRUG INTERMITTENT THERAPY; ECG ABNORMALITY; EXERCISE TOLERANCE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; FUNDING; GASTROINTESTINAL SYMPTOM; HEARING IMPAIRMENT; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; INFECTION PREVENTION; INFORMATION PROCESSING; INTENTION TO TREAT ANALYSIS; LONG QT SYNDROME; LUNG INFECTION; MUSCULOSKELETAL DISEASE; NEUROLOGIC DISEASE; ODDS RATIO; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY TRACT DISEASE; REVIEW; RISK ASSESSMENT; SENSITIVITY ANALYSIS; SHORT FORM 12; SHORT FORM 36; SIX MINUTE WALK TEST; ST. GEORGE RESPIRATORY QUESTIONNAIRE; SYSTEMATIC REVIEW; TINNITUS; TREATMENT DURATION; TREATMENT OUTCOME; AGED; DRUG ADMINISTRATION; META ANALYSIS; PROCEDURES;

AGED; AMOXICILLIN; ANTI-BACTERIAL AGENTS; ANTIBIOTIC PROPHYLAXIS; AZA COMPOUNDS; AZITHROMYCIN; CLARITHROMYCIN; CLAVULANIC ACID; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; ERYTHROMYCIN; FLUOROQUINOLONES; HUMANS; MOXIFLOXACIN; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUALITY OF LIFE; QUINOLINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; ROXITHROMYCIN; TRIMETHOPRIM, SULFAMETHOXAZOLE DRUG COMBINATION;

EID: 85055789723     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD009764.pub3     Document Type: Review

References (119)

1. Albert RK, Connett J, Bailey WC, Casaburi R, Cooper JA, Criner GJ, et al. Azithromycin for prevention of exacerbations of COPD. New England Journal of Medicine 2011;365:689-98. 9375030
2. Han MK, Tayob N, Murray S, Dransfield MT, Washko G, Scanlon PD, et al. Predictors of chronic obstructive pulmonary disease exacerbation reduction in response to daily azithromycin therapy. American Journal of Respiratory and Critical Care Medicine 2014;189(12):1503-8. 9375031
3. Martinez FJ, Connett J, Voelker H, Criner GJ, Han MK, Make BJ, et al. Chronic azithromycin therapy decreases the risk of re-hospitalization in patients with COPD. American Journal of Respiratory and Critical Care Medicine 2013;187:A4383. 9375032
4. O'Reilly PJ, Jackson PL, Wells JM, Dransfield MT, Scanlon PD, Blalock, JE. Sputum PGP is reduced by azithromycin treatment in patients with COPD and correlates with exacerbations. BMJ Open 2013;3(12):e004140. 9375033
5. Woodruff PG, Chatila W, Connett JE, Criner GJ, Curtis JL, Dransfield MT, et al. Tumour necrosis factor receptor-75 and risk of COPD exacerbation in the azithromycin trial. European Respiratory Journal 2014;43:295-8. 9375034
6. Banerjee D, Honeybourne D, Khair OA. The effect of oral Clarithromycin on bronchial airway inflammation in moderate-to-severe stable COPD: a randomised controlled trial. Treatments in Respiratory Medicine 2004;3:59-65. 9375036
7. Banerjee D, Khair O, Honeybourne D. The effect of oral clarithromycin on health status and sputum bacteriology in stable COPD. Respiratory Medicine 2005;99:208-15. 9375037
8. Berkhof FF, Doornewaard-ten Hertog NE, Uil SM, Kerstjens HAM, Van den Berg JWK. Azithromycin and cough-specific health status in patients with chronic obstructive pulmonary disease and chronic cough: a randomised controlled trial. Respiratory Research 2013;14(1):125. 9375039
9. Berkhof FF, Ten Hertog NE, Uil SM, Kerstjens HAM, Van Den Berg JK, CACTUS study group. Randomized controlled trial of prophylactic azithromycin on cough-specific health status in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine 2013;187:A2449. 9375040
10. Brill S, James P, Cuthbertson L, Cookson W, Moffatt M, Wedzicha J. Haemophilus dominance of the stable COPD microbiome is associated with greater bacterial load and inflammation and is modulated by prophylactic antibiotic therapy. European Respiratory Journal 2015;46:OA4746. 9375042
11. Brill S, Law M, Allinson J, El-Emir E, McHugh T, Donaldson G, et al. Bacterial resistance induction with prophylactic antibiotics in COPD. European Respiratory Journal 2014;44:P4731. 9375043
12. Brill SE, Law M, El-Emir E, Allinson JP, James P, Maddox V, et al. Effects of different antibiotic classes on airway bacteria in stable COPD using culture and molecular techniques: a randomised controlled trial. Thorax 2015;70(10):930-8. 9375044
13. Brill SE, Law M, El-Emir E, Allinson P, Nazareth I, Donaldson GC, et al. Effect of antibiotics on airway bacteria in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine 2014;198:A2874. 9375045
14. He ZY, Ou LM, Zhang JQ, Bai J, Liu GN, Li MH, et al. Effect of 6 months of erythromycin treatment on inflammatory cells in induced sputum and exacerbations in chronic obstructive pulmonary disease. Respiration 2010;80:445-52. 2721534
15. Mygind LH, Pedersen C, Vestbo J, Christensen JJ, Frimodt-Moller N, Kristiansen IS, et al. A randomised, placebo-controlled 3 years study of prophylactic azithromycin in 575 patients with chronic obstructive pulmonary disease. European Respiratory Society 20th Annual Congress; 2010 Sep 18-22; Barcelona. 2010. 2721536
16. NCT00524095. Bronchiectasis in chronic obstructive pulmonary disease (COPD) patients: role of prophylaxis. clinicaltrials.gov/ct2/show/NCT00524095 (first received 3 September 2007). 9375047
17. Batista CM. A bench to bedside investigation into defective innate immunity in chronic obstructive pulmonary disease. National Heart & Lung Institute, Imperial College London, UK; 2018. 9375049
18. NCT02628769. A study to evaluate the anti-inflammatory effects of solithromycin in chronic obstructive pulmonary disease. clinicaltrials.gov/ct2/show/NCT02628769 (first received 11 December 2015). 9375050
19. Seemungal TA, Wilkinson TM, Hurst JR, Perera WR, Sapsford RJ, Wedzicha JA. Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations. American Journal of Respiratory and Critical Care Medicine 2008;178:1139-47. 2721538
20. Sethi S, Jones PW, Theron MS, Miravitlles M, Rubinstein E, Wedzicha JA, et al. Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized control trial. Respiratory Research 2010;11:10. 2721540
21. Shafuddin E, Mills GD, Holmes MD, Poole PJ, Mullins PR, Black PN. A double-blind, randomised, placebo-controlled study of roxithromycin and doxycycline combination, roxithromycin alone, or matching placebo for 12 weeks in adults with frequent exacerbations of chronic obstructive pulmonary disease. Journal of Negative Results in Biomedicine 2015;14:15. [DOI: 10.1186/s12952-015-0034-8]9375052
22. Simpson JL, Powell H, Baines KJ, Milne D, Coxson HO, Hansbro PM, et al. The effect of azithromycin in adults with stable neutrophilic COPD: a double blind randomised, placebo controlled trial. PLOS One 2014;9(8):e105609. 9375054
23. Suzuki T, Yani M, Yamaya M, Satoh Nakagawa T, Sekizawa K, Ishida S, et al. Erythromycin and common cold in COPD. Chest 2001;120:730-3. 2721542
24. Tan C, Huang H, Zhang J, He Z, Zhong X, Bai J. Effects of low-dose and long-term treatment with erythromycin on IL-17 and IL-23 in peripheral blood and induced sputum in patients with stable chronic obstructive pulmonary disease. Chest 2016;149:387A. 9375056
25. Tan C, Huang H, Zhang J, He Z, Zhong X, Bai J. Effects of low-dose and long-term treatment with erythromycin on interleukin-17 and interleukin-23 in peripheral blood and induced sputum in patients with stable chronic obstructive pulmonary disease. Mediators of Inflammation 2016:4173962. [DOI: 10.1155/2016/4173962]9375057
26. Djamin RS, Uzun S, Ermens AAM, Kerstens R, Hoogsteden HC, Aerts JGJV, et al. Which predictors in COPD patients with the frequent exacerbator phenotype predict the treatment response to maintenance therapy with azithromycin?. European Respiratory Journal 2016;48:PA3713. 9375059
27. Uzun S, Djamin RS, Aerts JGJV, Van Der Eerden MM. Patients with COPD Gold C & D: the effect of long-term treatment with azithromycin on exacerbation risk assessed by the Gold Framework. American Journal of Respiratory and Critical Care Medicine 2014;189:A5967. 9375060
28. Uzun S, Djamin RS, Kluytmans JA, Mulder PG, Van't Veer NE, Ermens AA, et al. Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): a randomised, double-blind, placebo-controlled trial. Lancet Respiratory Medicine 2014;2(5):361-8. 9375061
29. Uzun S, Djamin RS, Mulder PGH, Kluytmans JAJW, Pelle AJ, Van't Veer NE, et al. Effect of azithromycin maintenance treatment in patients with frequent exacerbations of COPD (columbus): a randomized, double-blind, placebo-controlled trial. American Journal of Respiratory and Critical Care Medicine 2014;189:A2884. 9375062
30. Wang P, Yang J, Yang Y, Ding Z. Effect of azithromycin in combination with simvastatin in the treatment of chronic obstructive pulmonary disease complicated by pulmonary arterial hypertension. Pakistan Journal of Medicine Science 2017;33(2):260-4. 9375064
31. Beeh K-M, Beier J, Candler H, Wittig T. Effect of ELOM-080 on exacerbations and symptoms in COPD patients with a chronic bronchitis phenotype - a post-hoc analysis of a randomized, double-blind, placebo-controlled clinical trial. International Journal of COPD 2016;11(1):2877-84. 9375066
32. Beier VA. Trial of preventive treatment of patients with chronic bronchitis [Versuch einer prophylaktischen Behandlung chronischer Bronchitiker]. Wiener Medizinische Wochenschrift 1971;37:642-3. 2721546
33. Blasi F, Bonardi D, Aliberti S. Long term azithromycin use in patients with chronic obstructive pulmonary disease and tracheostomy. Pulmonary Pharmacology and Theraputics 2010;23:200-7. 2721548
34. Bruninx M, Koster J, Golard P, Libert P, Minette A, Mottard L, et al. Prophylactic administration of Bactrim in chronic bronchitis. Acta Tuberculosea et Pneumologica Belgica 1973;5-6:483-502. 2721550
35. Buchanan J, Buchanan W, Melrose A, McGuinness J, Price A. Long term prophylactic administration of tetracycline to chronic bronchitis. Lancet 1958;2(7049):719-22. 2721552
36. Bussi S, Murciano D, Botto MJ, Pariente R. Assessment of chemoprophylaxis with intermittent tetracycline in chronic-bronchitis - a functional follow-up for 3 years. Revue Francaise des Maladies Respiratoires 1980;8(5):351-6. 2721554
37. Davies A, Grobow E, Tompsett R, McClement J. Bacterial Infection and some effects of chemoprophylaxis in chronic pulmonary emphysema. American Journal of Medicine 1961;31:365-81. 2721558
38. Douglas A, Somner A, Marks B, Grant I. Effect of antibiotics on purulent sputum. Lancet 1957;273(6988):214-8. 2721560
39. Edwards G, Fear E. Adult chronic bronchitis - continuous antibiotic therapy. British Medical Journal 1958;2(5103):1010-2. 2721562
40. Elmes P, Fletcher C, Dutton A. Prophylactic use of oxytetracycline for exacerbations of chronic bronchitis. British Medical Journal 1957;2(5056):1272-5. 2721564
41. Calder M, Lutz W, Schonell ME. A five year study of bacteriology and prophylactic chemotherapy in patients with chronic bronchitis. British Journal of Diseases of the Chest 1968;62:93-9. 9375067
42. Fletcher DM, Ball JD, Carstairs LW, Cooch AHC, Crofton JM, Edge JR, et al. Value of chemoprophylaxis and chemotherapy in early chronic bronchitis. A report to the Medical Research Council by their working party on trials of chemotherapy in early chronic bronchitis. British Medical Journal 1966;1:1317-22. 2721566
43. Frances R, May J, Spicer C. Influence of daily penicillin, tetracycline, erythromycin and sulphamethoxypyridazine on exacerbation of bronchitis. British Medical Journal 1964;1:728-32. 2721568
44. Francis R, Spicer C. Chemotherapy in chronic bronchitis. Influence of daily penicillin and tetracycline on exacerbations and their cost. British Medical Journal 1960;30(1):297-303. 2721570
45. Goslings W, Djajadiningrat R, Bergstein P, Holle P. Continous suppressive antimicrobial treatment in chronic infected bronchitis during winter months. Disease of the Chest 1967;52(3):376-80. 2721572
46. Grossman R, Mukherjee J, Vaughan D, Cook R, LaForge J, Lampron N, et al. A 1-year community based health economic study of ciprofloxacin treatment in acute exacerbations of chronic bronchitis: the Canadian Ciprofloxacin Health Economics Study Group. Chest 1998;113:131-41. 2721574
47. Torrance G, Walker V, Grossman R, Mukherjee J, Vaughan D, La Forge J, et al. Economic evaluation of ciprofloxacin compared with usual anti-bacterial care for the treatment of acute exacerbations of chronic bronchitis in patients followed for 1 year. Pharmacoeconomics 1999;16:499-520. 9375068
48. Hahn HH, MacGregor RR, Counts CK, Smith HE, Beaty HN. Ampicillin and tetracyclin in the treatment and prophylaxis of chronic bronchitis. Antimicrobial Agents and Chemotherapy 1972;2(1):45-8. 2721576
49. Haidl P, Bargon J, Gessler T, Pfeifer M, Randerath W, Voshaar T, et al. Effect of inhalation of tobramycin for 12 months on reduction of hospitalisation rate in severe COPD. Pneumologie 2013;67(9):514-9. 9375070
50. Hallet WY, Beali GN, Kirby WMM. Chemoprophylaxis in chronic obstructive pulmonary emphysema. Chemoprophylaxis in Emphysema 1959;80:716-23. 2721578
51. Helm W, May JR, Livingstone JL. Long-term oxytetracycline (Terramycin) therapy in advanced chronic respiratory infections. Lancet 1956;267(6839):775-7. 2721580
52. Johnston R, Lockhart W, Smith D, Cadman D. A trial of phenethicillin in chronic bronchitis. British Medical Journal 1961;2(5258):985-6. 2721582
53. Johnston R, McNeil R, Smith D, Dempster M, Nairn J, Purvis M, et al. Five year winter prophylaxis for chronic bronchitis. British Medical Journal 1969;4:265-9. 2721584
54. Kilpatrick G, Oldham P. Sulphonmide prophylaxis in chronic bronchitis. British Medical Journal 1954;2(4884):385-7. 2721586
55. Legler F, Jansen W. Double blind long term study on a combination of tetracycline, theophylline, doxylamine succinate, etafedrine, phenylephedrine and guaifenesine in chronic bronchitis. Arzneimittel-Forschung 1977;27:883-8. 2721588
56. Liippo K, Pelliniemi T, Lehto H. Trimethoprim prophylaxis of acute exacerbations in chronic obstructive pulmonary disease. Acta Medica Scandinavica 1987;221:455-9. 2721590
57. Maraffi T, Piffer F, Cosentini R. Prophylactic antibiotic therapy in chronic obstructive pulmonary disease. Theraputic Advances in Respiratory Disease 2010;4:135-7. 2721592
58. Matthys H, Malek FA. Antibiotic use in patients with COPD receiving EPs 7630 as an add-on treatment. Atemwegs-und Lungenkrankheiten 2016;41(1):27-34. 9375072
59. May RJ. Long term chemotherapy in chronic bronchitis. Lancet 1956;271(6947):814-9. 9375074
60. Miravitlles M, Marin A, Monso E, Vila S, de la Roza C, Hervas R, et al. Efficacy of moxifloxacin in the treatment of bronchial colonisation in COPD. European Respiratory Journal 2009;34:1066-71. 2721596
61. Moyes EN, Kalinowski SZ. Prophylactic chemotherapy in chronic bronchitis. Tubercle 1959;40:112-8. 2721598
62. Murdoch J, Leckie W, Downie J, Swain R, Gould J. An evaluation of continuous antibiotic therapy in chronic bronchitis. British Medical Journal 1959;2(5162):1277-85. 2721600
63. Murray EA. A trial of ampicillin in chronic bronchitis. Journal of the College of General Practitioners 1964;7:244-52. 2721602
64. Nicholson TT, Franciosi A, Landers S, Butler MW. Assessing potential risks of treatment with long-term azithromycin in COPD patients: long-term oxygen users beware?. Irish Journal of Medical Science 2016;185(4):993-7. 9375076
65. Norman PS, Hook EW, Petersdorf RG, Cluff LE, Godfrey MP, Levy AH. Long term tetracycline treatment of chronic bronchitis. JAMA 1962;179(11):833-7. 2721604
66. Pines A. Controlled trials of a sulphonamide given weekly to prevent exacerbations of chronic bronchitis. British Medical Journal 1967;3:202-4. 2721606
67. Pridie RB, Datta N, Massey DG, Poole GW, Schneeweiss J, Stradling P, et al. A trial of continuous winter chemotherapy in chronic bronchitis. Lancet 1960;2(7153):723-7. 2721608
68. Prins HJ, Daniels JM, Lindeman JH, Lutter R, Boersma WG. Effects of doxycycline on local and systemic inflammation in stable COPD patients, a randomized clinical trial. Respiratory Medicine 2016;110:46-52. 9375078
69. Ras J, Anderson R, Eftychis H, Koch U, Theron A, Vanwyk H, et al. Chemoprophylaxis with erythromycin stearate or amoxacillin in patients with chronic bronchitis - effects on cellular and humoral immune functions. South African Medical Journal 1984;66:955-8. 2721610
70. Segal LN, Clemente JC, Wu BG, Wikoff WR, Gao Z, Li Y, et al. Randomised, double-blind, placebo-controlled trial with azithromycin selects for anti-inflammatory microbial metabolites in the emphysematous lung. Thorax 2017;72(1):13-22. 9375080
71. Segal LN, Wu B, Clemente J, Wikof W, Alekseyenko A, Berger KI, et al. Effects of azithromycin on lung microbiome, metabolome and immune phenotype of early emphysema subjects: a randomized controlled pilot study (Abstract). American Journal of Respiratory and Critical Care Medicine 2017;189:A2475. 9375081
72. Siva R, Bafadhel M, Monteiro W, Brightling CE, Pavord ID. Effect of levofloxacin on neutrophilic airway inflammation in stable COPD: a randomized, double-blind, placebo-controlled trial. International Journal of Chronic Obstructive Pulmonary Disease 2014;9:179-86. 9375083
73. Stass H, Nagelschmitz J, Kappeler D, Weimann B. Lung deposition of ciprofloxacin dry powder for inhalation in healthy subjects and patients suffering from chronic obstructive pulmonary disease or non-cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine 2013;187:A1507. 9375085
74. Vandenbergh E, Clement J, Woestijne K. Prevention of exacerbations of bronchitis: trial of a long acting sulphonamide. British Journal of Diseases of the Chest 1970;64:58-62. 2721616
75. Van Velzen P, Ter Riet G, Bresser P, Van Den Berg BTJ, Van Den Berg WK, Daniels MA. Long-term effects of antibiotics in COPD exacerbations: a randomized clinical trial. American Journal of Respiratory and Critical Care Medicine 2016;193:A1021. 9375087
76. Vermeersch K, Everaerts S, Ninane V, Gabrovska M, Aumann J, Deslypere G, et al. Time-to-treatment failure in the Belgian randomized controlled trial with azithromycin for acute COPD exacerbations requiring hospitalization. European Respiratory Journal 2016;48:OA1506. 9375089
77. Vermeersch K, Gabrovska M, Deslypere G, Demedts IK, Slabbynck H, Aumann J, et al. The Belgian trial with azithromycin for acute COPD exacerbations requiring hospitalization: an investigator-initiated study protocol for a multicenter, randomized, double-blind, placebo-controlled trial. International Journal of Chronic Obstructive Pulmonary Disease 2016;11:687-96. 9375090
78. Watanabe A. Once daily versus every two week multidose ofloxacin in patients with acute exacerbations of chronic respiratory disease. Infection 1991;19:S384-7. 2721618
79. Watanabe A, Motomiya M, Nukiwa T, Nakai Y, Honda Y, Konno K. A well-controlled comparative clinical study of the combination regimen of ciprofloxacin plus erythromycin for the treatment of repeated acute exacerbations of chronic respiratory tract infections. Chemotherapy 1994;42:1194-201. 2721620
80. Watanabe A, Oizumi K, Motomiya M, Nukiwa T. Daily single-dose regimen and alternate two-week triple dose/day regimen of oral ofloxacin for the prophylaxis and control of exacerbations of chronic respiratory tract infections. Tohoku Journal of Experimental Medicine 1995;176:25-33. 2721622
81. Webster I. A double blind cross-over trail of trimethoprim and sulphamethoxazole in chronic bronchitis. Thorax 1971;26:319-24. 2721624
82. Milito C, Pulvirenti F, Tabolli S, Carello R. Antibiotic prophylaxis in primary antibody deficiency patients: study design PT. Journal of Clinical Immunology 2017;37:240-1. 9375092
83. ChiCTR-IOR-16008820. Effect of low-dose erythromycin on the treatment of COPD. apps.who.int/trialsearch/Trial2.aspx?TrialID=ChiCTR-IOR-16008820 (first received 11 July 2016). 9375094
84. NCT02205242. BACE trial substudy 1 - PROactive substudy (PROactive). clinicaltrials.gov/show/NCT02205242 (first received 31 July 2014). 9375096
85. NCT02205255. BACE trial substudy 2 - FarmEc substudy (FarmEc). clinicaltrials.gov/ct2/show/NCT02205255 (first received 31 July 2014). 9375098
86. NCT02305940. Effects of long term antibiotic therapy on exacerbation rate in stable COPD patients. clinicaltrials.gov/show/NCT02305940 (first received 3 December 2014). 9375100
87. Beasley V, Joshi P, Singanayagam A, Molyneaux P, Johnston SL, Mallia P. Lung microbiology and exacerbations in COPD. International Journal of Chronic Obstructive Pulmonary Disease 2012;7:555-69. [DOI: 10.2147/COPD.S28286; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3437812/]
88. Birring SS, Prudon B, Carr AJ, Singh SJ, Morgan MDL, Pavord ID. Development of a symptom specific health status measure for patients with chronic cough: Leicester Cough Questionnaire (LCQ). Thorax 2003;58(4):339-43.
89. Joint Formulary Committee. British National Formulary. London: BMJ Group and Pharmaceutical Press, 2018. [http://www.medicinescomplete.com]
90. Chong J, Leung B, Poole P. Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2017, Issue 9. [DOI: 10.1002/14651858.CD002309.pub3]
91. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (2018 report). goldcopd.org/wp-content/uploads/2017/11/GOLD-2018-v6.0-FINAL-revised-20-Nov_WMS.pdf (accessed prior to 20 July 2018).
92. Guyatt G, Berman L, Townsend M, Pugsley S, Chambers L. A measure of quality of life for clinical trials in chronic lung disease. Thorax 1987;42:773-8.
93. Harries TH, Thornton HV, Crichton S, Schofield P, Gilkes A, White PT. Length of stay of COPD hospital admissions between 2006 and 2010: a retrospective longitudinal study. International Journal of Chronic Obstructive Pulmonary Disease 2015;10:603-11.
94. Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
95. Hurst JR, Perera WR, Wilkinson TMA, Donaldson GC, Wedzicha JA. Systemic and upper and lower airway inflammation at exacerbation of chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine 2006;173:71-8.
96. Jones P. St George's Respiratory Questionnaire Manual Version 2.3. www.healthstatus.sgul.ac.uk/SGRQ_download/SGRQ%20Manual%20June%202009.pdf (accessed prior to 20 July 2018).
97. Kew KM, Seniukovich A. Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2014, Issue 3. [DOI: 10.1002/14651858.CD010115.pub2]
98. Lee TA, Pharm D, Weaver FM. Impact of pneumococcal vaccination on pneumonia rates in patients with COPD and asthma. Journal of General Internal Medicine 2007;22(1):62-7.
99. Martinez FJ, Curtis JL, Albery R. Role of macrolide therapy in chronic obstructive pulmonary disease. International Journal of Chronic Obstructive Pulmonary Disease 2008;3:331-50. [PUBMED: 18990961]
100. Martinez-Garcia MA, Miravitlles M. Bronchiectasis in COPD patients: more than a comorbidity?. International Journal of Chronic Obstructive Pulmonary Disease 2017;12:1401-11.
101. Matkovic Z, Miravitlles M. Chronic bronchial infection in COPD. Is there an infective phenotype?. Respiratory Medicine 2013;107:10-22.
102. Matzneller P, Krasniqi S, Kinzig M, Sörgel F, Hüttner S, Lackner E, et al. Blood, tissue, and intracellular concentrations of azithromycin during and after end of therapy. Antimicrobial Agents and Chemotherapy 2013;57(4):1736-42.
103. Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan - a web and mobile app for systematic reviews. Systematic Reviews 2016;5(1):210. [DOI: 10.1186/s13643-016-0384-4]
104. Papi A, Luppi F, Franco F, Fabbri LM. Pathophysiology of exacerbations of chronic obstructive pulmonary disease. Proceedings of the American Thoracic Society 2006;3:3. [http://www.atsjournals.org/doi/full/10.1513/pats.200512-125SF]
105. Poole P, Black PN, Cates CJ. Mucolytic agents for chronic bronchitis or chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2012, Issue 8. [DOI: 10.1002/14651858.CD001287.pub4]
106. Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3.5. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2008.
107. Sapey E, Stockley RA. COPD exacerbations 2: aetiology. Thorax 2006;61(3):250-8.
108. Sethi S, Murphy TF. Infection in the pathogenesis and course of chronic obstructive pulmonary disease. New England Journal of Medicine 2008;359:2355-65.
109. Staykova T, Black PN, Chacko EE, Poole P. Prophylactic antibiotic therapy for chronic bronchitis. Cochrane Database of Systematic Reviews 2003, Issue 1. [DOI: 10.1002/14651858.CD004105]
110. Kardos P, Wencker M, Glaab T, Vogelmeier C. Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine 2007;175(144):149.
111. Thoracic Society of Australia and New Zealand (New Zealand Branch). Standards for adult respiratory and sleep services in New Zealand. www.health.govt.nz/system/./standardsforadultrespiratoryandsleepservices.doc (accessed prior to 20 July 2018).
112. Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S, et al. 4-year trial of tiotropium in chronic obstructive pulmonary disease. New England Journal of Medicine 2008;359:1543-54.
113. Visual Rx. www.nntonline.net/visualrx/ (accessed October 2013).
114. Wang J, Nie B, Xiong W, Xu Y. Effect of long-acting beta-agonists on the frequency of COPD exacerbations: a meta-analysis. Journal of Clinical Pharmacy and Therapeutics 2012;37:204-11.
115. Wenzel RP, Fowler AA, Edmond MB. Antibiotic prevention of acute exacerbations of COPD. New England Journal of Medicine 2012;367(4):340-7.
116. World Health Organization. Chronic obstructive pulmonary disease. www.who.int/respiratory/copd/en/ (accessed 18 November 2011).
117. Wilkinson T, Hurst J, Perera W, Wilks M, Donaldson G, Wedzicha J. Effects of interactions between lower airway bacterial and rhinoviral infections in exacerbations of COPD. Chest 2006;129(2):317-24. [http://www.sciencedirect.com/science/article/pii/S0012369215387523?via%3Dihub]
118. Woodhead M, Blasi F, Ewig S, Garau J, Huchon G, Leven M, et al. Guidelines for the management of adult lower respiratory tract infections. Clinical Microbiology and Infection 2011;17(6):E1-E59. [https://doi.org/10.1111/j.1469-0691.2011.03672.x]
119. Herath S, Poole P. Prophylactic antibiotic therapy for chronic obstructive pulmonary disease (COPD). Cochrane Database of Systematic Reviews 2013, Issue 11. [DOI: 10.1002/14651858.CD009764.pub2]